The current status of oncolytic viral therapy for head and neck cancer

Objective: Cancer affects the head and neck region frequently and leads to significant morbidity and mortality. Oncolytic viral therapy has the potential to make a big impact in cancers that affect the head and neck. We intend to review the current state of oncolytic viruses in the treatment of canc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Matthew O. Old, Trisha Wise-Draper, Chadwick L. Wright, Balveen Kaur, Theodoros Teknos
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2016
Materias:	Otorhinolaryngology RF1-547 Surgery RD1-811
Acceso en línea:	https://doaj.org/article/34cab34b5fac43da9edc149f58400b27
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:34cab34b5fac43da9edc149f58400b27
record_format	dspace
spelling	oai:doaj.org-article:34cab34b5fac43da9edc149f58400b272021-12-02T13:21:40ZThe current status of oncolytic viral therapy for head and neck cancer2095-881110.1016/j.wjorl.2016.05.009https://doaj.org/article/34cab34b5fac43da9edc149f58400b272016-06-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095881116300178https://doaj.org/toc/2095-8811Objective: Cancer affects the head and neck region frequently and leads to significant morbidity and mortality. Oncolytic viral therapy has the potential to make a big impact in cancers that affect the head and neck. We intend to review the current state of oncolytic viruses in the treatment of cancers that affect the head and neck region. Method: Data sources are from National clinical trials database, literature, and current research. Results: There are many past and active trials for oncolytic viruses that show promise for treating cancers of the head and neck. The first oncolytic virus was approved by the FDA October 2015 (T-VEC, Amgen) for the treatment of melanoma. Active translational research continues for this and many other oncolytic viruses. Conclusion: The evolving field of oncolytic viruses is impacting the treatment of head and neck cancer and further trials and agents are moving forward in the coming years. Keywords: Head and neck squamous cell carcinoma, Oncolytic viruses, Clinical trials, Novel therapeuticsMatthew O. OldTrisha Wise-DraperChadwick L. WrightBalveen KaurTheodoros TeknosKeAi Communications Co., Ltd.articleOtorhinolaryngologyRF1-547SurgeryRD1-811ENWorld Journal of Otorhinolaryngology-Head and Neck Surgery, Vol 2, Iss 2, Pp 84-89 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Otorhinolaryngology RF1-547 Surgery RD1-811
spellingShingle	Otorhinolaryngology RF1-547 Surgery RD1-811 Matthew O. Old Trisha Wise-Draper Chadwick L. Wright Balveen Kaur Theodoros Teknos The current status of oncolytic viral therapy for head and neck cancer
description	Objective: Cancer affects the head and neck region frequently and leads to significant morbidity and mortality. Oncolytic viral therapy has the potential to make a big impact in cancers that affect the head and neck. We intend to review the current state of oncolytic viruses in the treatment of cancers that affect the head and neck region. Method: Data sources are from National clinical trials database, literature, and current research. Results: There are many past and active trials for oncolytic viruses that show promise for treating cancers of the head and neck. The first oncolytic virus was approved by the FDA October 2015 (T-VEC, Amgen) for the treatment of melanoma. Active translational research continues for this and many other oncolytic viruses. Conclusion: The evolving field of oncolytic viruses is impacting the treatment of head and neck cancer and further trials and agents are moving forward in the coming years. Keywords: Head and neck squamous cell carcinoma, Oncolytic viruses, Clinical trials, Novel therapeutics
format	article
author	Matthew O. Old Trisha Wise-Draper Chadwick L. Wright Balveen Kaur Theodoros Teknos
author_facet	Matthew O. Old Trisha Wise-Draper Chadwick L. Wright Balveen Kaur Theodoros Teknos
author_sort	Matthew O. Old
title	The current status of oncolytic viral therapy for head and neck cancer
title_short	The current status of oncolytic viral therapy for head and neck cancer
title_full	The current status of oncolytic viral therapy for head and neck cancer
title_fullStr	The current status of oncolytic viral therapy for head and neck cancer
title_full_unstemmed	The current status of oncolytic viral therapy for head and neck cancer
title_sort	current status of oncolytic viral therapy for head and neck cancer
publisher	KeAi Communications Co., Ltd.
publishDate	2016
url	https://doaj.org/article/34cab34b5fac43da9edc149f58400b27
work_keys_str_mv	AT matthewoold thecurrentstatusofoncolyticviraltherapyforheadandneckcancer AT trishawisedraper thecurrentstatusofoncolyticviraltherapyforheadandneckcancer AT chadwicklwright thecurrentstatusofoncolyticviraltherapyforheadandneckcancer AT balveenkaur thecurrentstatusofoncolyticviraltherapyforheadandneckcancer AT theodorosteknos thecurrentstatusofoncolyticviraltherapyforheadandneckcancer AT matthewoold currentstatusofoncolyticviraltherapyforheadandneckcancer AT trishawisedraper currentstatusofoncolyticviraltherapyforheadandneckcancer AT chadwicklwright currentstatusofoncolyticviraltherapyforheadandneckcancer AT balveenkaur currentstatusofoncolyticviraltherapyforheadandneckcancer AT theodorosteknos currentstatusofoncolyticviraltherapyforheadandneckcancer
_version_	1718393141587869696

The current status of oncolytic viral therapy for head and neck cancer

Ejemplares similares